Hyperbilirubinemia Among African American, Glucose-6-Phosphate Dehydrogenase-Deficient Neonates

ABSTRACT. Background. Although glucose-6-phosphate dehydrogenase (G-6-PD) deficiency is prevalent in African Americans, their risk of associated neonatal hyperbilirubinemia has not been prospectively studied.

Objective. To compare hemolysis and the risk of hyperbilirubinemia among African American, G-6-PD-deficient neonates (study group) and G-6-PD-normal control subjects.

Methods. Consecutive, healthy, term and near-term, male neonates born to African American mothers comprised the patient cohort. G-6-PD testing was performed with umbilical cord blood samples. Routine management included measurement of the end tidal carbon monoxide level (ETCOc) within 4 hours after delivery (assessment of hemolysis), ≥1 predischARGE bilirubin determination, and additional bilirubin testing as clinically indicated. Indications for phototherapy were identical for study patients and control subjects. Neonates were monitored for the first 1 week of life. ETCOc results, the incidence of hyperbilirubinemia (defined as a transcutaneous or plasma total bilirubin concentration of ≥95th percentile for the hour of life), and the need for phototherapy were compared between the G-6-PD-deficient and G-6-PD-normal groups.

Results. Five hundred male patients were enrolled, of whom 64 (12.8%) were G-6-PD-deficient. ETCOc values (median and interquartile range) were higher among G-6-PD-deficient neonates than among control neonates (2.4 ppm [2.0–2.9 ppm] vs 2.1 ppm [1.7–2.5 ppm]). More G-6-PD-deficient neonates developed hyperbilirubinemia than did control subjects (14 of 64, 21.9%, vs 29 of 436, 6.7%; relative risk: 3.27, 95% confidence interval: 1.83–5.86), whereas 13 (20.3%) met the criteria for phototherapy, compared with 25 control subjects (5.7%) (relative risk: 3.53; 95% confidence interval: 1.91–6.56). No cases of kernicterus were observed.

Conclusions. Within the African American neonatal population, there is a subgroup of G-6-PD-deficient infants with elevated rates of hemolysis, a higher incidence of hyperbilirubinemia, and a greater requirement for phototherapy, compared with G-6-PD-normal control subjects. These newborns should be monitored vigilantly for the development of hyperbilirubinemia. Pediatrics 2004;114:e213–e219. URL: http://www.pediatrics.org/cgi/content/full/114/2/e213; glucose-6-phosphate dehydrogenase deficiency, African American, hemolysis, neonatal hyperbilirubinemia, kernicterus, phototherapy, bilirubin, end tidal carbon monoxide.

ABBREVIATIONS. ETCOc, end tidal carbon monoxide level corrected for ambient carbon monoxide; G-6-PD, glucose-6-phosphate dehydrogenase; PTB, plasma total bilirubin; TcB, transcutaneous bilirubin; Hb, hemoglobin.

Despite increasing awareness of neonatal hyperbilirubinemia and American Academy of Pediatrics guidelines for the management of this condition, kernicterus continues to be encountered in North America. Because many of the reported neonates were also deficient in glucose-6-phosphate dehydrogenase (G-6-PD), a condition associated with hyperbilirubinemia and kernicterus, an etiologic factor linking these 2 conditions is likely. African Americans, of whom 11% to 13% are known to be G-6-PD-deficient (G-6-PD A−), represent the largest subgroup affected in North America. Traditionally, these newborns have not been regarded as being at high risk for G-6-PD deficiency-associated hyperbilirubinemia; Maisels and Newman stated that many American pediatricians do not take G-6-PD deficiency into consideration when evaluating likely causes of severe neonatal hyperbilirubinemia. This view was supported by the finding of Brown et al that few neonates readmitted for treatment of hyperbilirubinemia in the greater New York City area had been tested for G-6-PD deficiency.

The incidence and severity of G-6-PD deficiency-associated neonatal hyperbilirubinemia among African American neonates are largely unknown, because no large prospective study has been performed to date. The primary aim of this study was to determine prospectively the risk of developing hyperbilirubinemia, and the severity thereof, among a cohort of healthy, male, term and near-term, African American, G-6-PD-deficient neonates and to compare the findings with those for G-6-PD-normal counterparts. We also compared the degree of hemolysis, a risk factor for kernicterus, between the 2 groups, using an end tidal carbon monoxide technique.
METHODS

Patients and Treatment

The study was performed in the general care (well-infant) nursery of the University of Chicago Hospitals (Chicago, IL), with the approval of the review board of that institution. This hospital has ~3000 deliveries annually, 87% with African American mothers. Signed informed consent was obtained from at least 1 parent of each neonate enrolled in the study.

Eligibility for enrollment were healthy male neonates who were born to African American mothers. Criteria for exclusion included transfer to the neonatal intensive care unit for reasons including major congenital anomalies, sepsis, respiratory distress or oxygen requirement, and hypoglycemia requiring intravenous glucose therapy. The study was limited to male subjects because, inasmuch as G-6-PD deficiency is an X-linked condition, the G-6-PD status can be accurately determined for male subjects, who can be either normal or deficient hemizygotes. Among female subjects, a large number of G-6-PD-deficient heterozygotes, with a form of the condition that may be difficult to diagnose, may be encountered.16

Because results of the G-6-PD testing usually became available only after discharge, infants in the 2 groups were treated identically, and differentiation into G-6-PD-deficient and -normal groups was performed only retrospectively. For all neonates enrolled in the study, a sample of umbilical cord blood was collected for G-6-PD biochemical analysis. Umbilical cord blood was also used to test neonates born to Rh-negative mothers, who were extended to these neonates was routine. Breastfeeding was encouraged, and healthy infants were hospitalized for ~48 hours.

Management of neonatal jaundice was as follows. Nursery protocol included measurement of the end tidal carbon monoxide level corrected for ambient carbon monoxide level (ETCOc) within 4 hours after delivery. At least 1 predischARGE transcutaneous bilirubin (TcB) test was performed for each neonate at 48 ± 12 hours of age, except for neonates who were already receiving phototherapy before that age. TcB readings of ≥15.0 mg/dL were confirmed with plasma total bilirubin (PTB) determinations. Additional TcB or PTB determinations were performed as deemed necessary according to the nomogram provided by Bhutani et al.17

Indications for phototherapy were based on those of the American Academy of Pediatrics Practice Parameter,18 as follows: PTB concentrations of ≥342 nmol/L (20.0 mg/dL) unless there were special risk factors, such as poor breastfeeding or parental anxiety, in which case an infant might be admitted with a PTB concentration of 108 to 342 µmol/L (15.0 to 20.0 mg/dL) between 25 and 48 hours, ≥255 µmol/L (15.0 mg/dL) between 49 and 72 hours, and ≥291 µmol/L (20.0 mg/dL) at ≥72 hours. Criteria for readmission for treatment of hyperbilirubinemia included PTB concentrations of ≥342 µmol/L (20.0 mg/dL) between 25 and 48 hours, ≥255 µmol/L (15.0 mg/dL) between 49 and 72 hours, and ≥291 µmol/L (20.0 mg/dL) at ≥72 hours. Criteria for admission to the phototherapy treatment, which was administered with 1 or 2 Draeger 4000 banks of phototherapy lights (Draeger Medical Inc, Tarrytown, NY), and enzyme activity was expressed as units per gram of hemoglobin (Hb). For reference, normal values for African American neonates have been reported as 287 ± 63 U/100 mL erythrocytes,11 which correspond to ~8.0 ± 1.5 mg/dL of Hb.20

TcB determinations were performed by using Bichlech (Respironics, Norcross, GA). PTB measurements were performed by using a spectrophotometrically monitored diazo reaction (Roche/Hitachi Modular P; Roche Diagnostics GmbH, Mannheim, Germany). The instrument was calibrated with a lyophilized control serum based on human serum (Precipath U plus; Roche Diagnostics).

The principle of the ETCOc test is that, for each molecule of biliverdin, and subsequently bilirubin, produced from the degradation of heme by the enzyme heme oxygenase, equimolar quantities of carbon monoxide are produced. This carbon monoxide is transported to the lungs in the form of carboxyhemoglobin. Measurement of ETCOc reflects endogenous carbon monoxide production. Because the majority of available heme is derived from heme degradation, accurate assessment of ETCOc provides an index of the rate of heme catabolism and therefore bilirubin production.15-24 ETCOc was measured with the CO-Stat end tidal breath analyzer (Natus Medical Inc, San Carlos, CA), which automatically corrects for ambient carbon monoxide levels. Results are expressed as parts per million. Because maternal cigarette smoking may increase blood carboxyhemoglobin levels for both the mother and the fetus, ETCOc values may be increased among newborns born to smoking mothers for up to 48 hours after delivery.25 Therefore, for ETCOc analyses, only the subgroup of newborns born to non-smoking mothers was included.

Definition

Hyperbilirubinemia was defined as any TcB or PTB value ≥95th percentile for the hour of life for which the sample was drawn, according to the nomogram provided by Bhutani et al.17

Sample Size

With the assumption of an incidence of hyperbilirubinemia among the G-6-PD-deficient neonates of 20% and an incidence in the control group of 6%, with a = .05 and power = .8, 52 patients in each group would be necessary. With the assumption of a 10% frequency of G-6-PD deficiency in the population studied, 500 neonates would need to be enrolled to yield the required 50 G-6-PD-deficient neonates.

Data Analyses

For analysis, patients were divided into the study group, ie, those who were G-6-PD-deficient, and the control group, with normal G-6-PD activity. The cohort was also arbitrarily subdivided into 3 subgroups according to the degree of bilirubinemia, ie, 1) neonates whose PTB concentrations for the hour of life did not exceed the 74th percentile, 2) neonates whose PTB concentrations were in ≥75th percentile for the hour of life, and 3) neonates designated hyperbilirubinemic (PTB concentrations in ≥95th percentile for the hour of life). The 75th percentile was chosen as the cutoff point to comply with nursery protocol, which mandated additional bilirubin testing for neonates with PTB concentrations in the upper quartile. Continuous variables were compared by using Student’s t test or the Mann-Whitney rank sum test, as appropriate, for data with or without normal distribution. Cate-
RESULTS

Enrollment

Study subjects were enrolled as consecutive births between September 2002 and May 2003. No mothers refused enrollment. One G-6-PD blood sample clotted, necessitating enrollment of 501 infants, although only 500 were included in the analysis.

G-6-PD Distribution

Of the 500 neonates, 64 (12.8%) were G-6-PD-deficient (mean enzyme activity: 2.76 ± 1.15 U/g Hb), whereas the remainder had normal enzyme activity (21.81 ± 2.88 U/g Hb). There was no overlap between the 2 groups.

Demographic Data

Demographic data for the neonates in both groups are summarized in Table 1. No significant differences were noted between the groups for any of the categories listed. Of 14 G-6-PD-deficient neonates who underwent direct Coombs’ testing, 1 exhibited positive results, compared with 3 of 60 G-6-PD-normal neonates (not significant).

Jaundice and Hyperbilirubinemia

Predischarge PTB concentrations (with the exclusion of 4 G-6-PD-deficient and 7 control neonates who began receiving phototherapy before 36 hours) were higher in the G-6-PD-deficient group than in the control group (157 ± 43 μmol/L vs 139 ± 48 μmol/L, P = .006 [9.2 ± 2.5 mg/dL vs 8.1 ± 2.8 mg/dL]). Within the G-6-PD-normal group, the distribution of PTB concentrations generally adhered to the expected results; 102 of 436 neonates (23.4%) developed PTB concentrations in ≥75th percentile for the hour of life, whereas 29 (6.7%) became hyperbilirubinemic (≥95th percentile). In contrast, 31 (48.4%, P < .001) and 14 (21.9%, P < .001) of the G-6-PD-deficient neonates developed PTB levels in ≥75th and ≥95th percentiles for the hour of life, respectively (Fig 1). The risk of G-6-PD-deficient neonates developing PTB concentrations in ≥75th percentile for the hour of life, relative to the G-6-PD-normal control subjects, was 2.07 (95% confidence interval: 1.53-2.81), whereas that of developing hyperbilirubinemia was 3.27 (95% confidence interval: 1.83-5.86). Among the neonates with PTB levels in ≥95th percentile, the highest noted PTB levels were similar between the 2 groups (245 ± 58 μmol/L vs 238 ± 53 μmol/L, P = .65 [14.3 ± 3.4 mg/dL vs 13.9 ± 3.1 mg/dL]), although these values do not represent the natural peak, because phototherapy had been instituted in many instances. Similarly, the ages at which the highest PTB levels were noted among those with PTB levels in ≥95th percentile were not significantly different between the groups (64 ± 27 hours vs 55 ± 23 hours, P = .3). No G-6-PD-deficient neonates were readmitted for treatment of hyperbilirubinemia, compared with 6 neonates (1.4%) in the control group (P = .7).

---

**Table 1.** Demographic Data for G-6-PD-Deficient Versus G-6-PD-Normal Male Neonates

<table>
<thead>
<tr>
<th>Category</th>
<th>G-6-PD-Deficient (n = 64)</th>
<th>G-6-PD-Normal (n = 436)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Birth weight, g</td>
<td>3232 ± 470</td>
<td>3271 ± 476</td>
</tr>
<tr>
<td>Gestational age, wk</td>
<td>38.9 ± 1.5</td>
<td>38.9 ± 1.5</td>
</tr>
<tr>
<td>Caesarian section, no.</td>
<td>19 (29.7%)</td>
<td>82 (18.8%)</td>
</tr>
<tr>
<td>Group B streptococcal colonization, no.</td>
<td>21/53 (39.6%)</td>
<td>133/356 (37.4%)</td>
</tr>
<tr>
<td>Breastfeeding (exclusive and mixed), no.</td>
<td>22 (34.4%)</td>
<td>174 (39.9%)</td>
</tr>
<tr>
<td>Maternal smoking, no.</td>
<td>5 (7.8%)</td>
<td>74 (16.9%)</td>
</tr>
<tr>
<td>Maternal diabetes mellitus, no.</td>
<td>2 (3.1%)</td>
<td>8 (1.8%)</td>
</tr>
<tr>
<td>Cephalhematoma or bruising, no.</td>
<td>2 (3.1%)</td>
<td>12 (2.6%)</td>
</tr>
</tbody>
</table>

No significant differences were found for any of these categories between the 2 groups.

---

Fig 1. Percentages of neonates with PTB concentrations of ≥75th percentile on the bilirubin nomogram timed for the hour of life, hyperbilirubinemia (≥95th percentile), and requirements for phototherapy, in the G-6-PD-deficient and control groups. For the former 2 parameters, the percentages of G-6-PD-normal neonates were similar to the expected distribution; however, within the G-6-PD-deficient group, the percentages of affected neonates were significantly higher than those of the G-6-PD-normal neonates (*relative risk: 2.07; 95% confidence interval: 1.53-2.81; **relative risk: 3.27; 95% confidence interval: 1.83-5.86; ***relative risk: 3.54; 95% confidence interval: 1.91-6.56).
TABLE 2. Data Relating to Phototherapy for the G-6-PD-Deficient and G-6-PD-Normal Neonatal Groups

<table>
<thead>
<tr>
<th>Category</th>
<th>G-6-PD-Deficient (n = 64)</th>
<th>G-6-PD-Normal (n = 436)</th>
<th>Significance (P Value)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. requiring phototherapy</td>
<td>13 (20.3%)*</td>
<td>25 (5.7%)</td>
<td>.6</td>
</tr>
<tr>
<td>Age at onset, h</td>
<td>50 ± 26</td>
<td>47 ± 26</td>
<td>.8</td>
</tr>
<tr>
<td>Age at discontinuation, h</td>
<td>82 ± 26</td>
<td>81 ± 20</td>
<td>.8</td>
</tr>
<tr>
<td>Duration of phototherapy, h</td>
<td>25 (17–33)</td>
<td>24 (20–50)</td>
<td>.5</td>
</tr>
<tr>
<td>PTB level at onset, μmol/L</td>
<td>245 ± 58</td>
<td>238 ± 53</td>
<td>.65</td>
</tr>
<tr>
<td>PTB level at onset, mg/dL</td>
<td>13.9 ± 3.4</td>
<td>13.2 ± 3.2</td>
<td>.9</td>
</tr>
<tr>
<td>Highest noted PTB level, μmol/L†</td>
<td>263 ± 46</td>
<td>251 ± 50</td>
<td>.5</td>
</tr>
<tr>
<td>(Highest noted PTB level, mg/dL)</td>
<td>15.4 ± 2.7</td>
<td>14.7 ± 2.9</td>
<td>.9</td>
</tr>
<tr>
<td>PTB level at discontinuation, μmol/L</td>
<td>162 ± 38</td>
<td>166 ± 21</td>
<td>.8</td>
</tr>
<tr>
<td>(PTB level at discontinuation, mg/dL)</td>
<td>9.5 ± 2.2</td>
<td>9.7 ± 1.2</td>
<td>.9</td>
</tr>
<tr>
<td>Rate of bilirubin decrease, μmol/h</td>
<td>3.1 ± 2.1</td>
<td>2.7 ± 2.9</td>
<td>.6</td>
</tr>
<tr>
<td>(Rate of bilirubin decrease, mg/h)</td>
<td>0.18 ± 0.12</td>
<td>0.16 ± 0.17</td>
<td>.9</td>
</tr>
</tbody>
</table>

Data are presented as mean ± SD or median (interquartile range), as appropriate.
* Relative risk: 3.54; 95% confidence interval: 1.91–6.56.
† Not the natural peak, because PTB concentrations might have been tempered by the institution of phototherapy.

Phototherapy

Significantly more G-6-PD-deficient neonates (13 neonates, 20.3%) required phototherapy, compared with 25 (5.7%) of the G-6-PD-normal group (P < .001). The relative risk of G-6-PD-deficient neonates requiring phototherapy, compared with G-6-PD-normal control subjects, was 3.54 (95% confidence interval: 1.91–6.56). Additional details regarding phototherapy are summarized in Table 2, in which it can be seen that, despite the greater number of G-6-PD-deficient neonates who required phototherapy, no significant differences between the groups with respect to any of the factors noted were observed.

ETCOc Studies

ETCOc values (median and interquartile range) were significantly higher in the G-6-PD-deficient group (n = 59) than in the control group (n = 363) (2.4 [2.0–2.9] ppm vs 2.1 [1.7–2.5] ppm, P < .001).

Contribution of G-6-PD Activity and Hemolysis to Bilirubin Grading

For the G-6-PD-deficient neonates, multivariate analysis (r = .2) demonstrated no significant correlation of either ETCOc values (P = .11) or residual G-6-PD enzymatic activity (P = .61) with bilirubinemia grading (defined in Data Analyses).

Prevalence of G-6-PD Deficiency and Hyperbilirubinemia

The prevalence of G-6-PD deficiency was greater among neonates with bilirubin values in ≥75th percentile (31 of 133 neonates, 23%) and ≥95th percentile (14 of 43 neonates, 32%), compared with the entire cohort (64 of 500 neonates, 12.8%; P = .004 and P = .001 for the 75th and 95th percentile comparisons, respectively).

DISCUSSION

Severe neonatal jaundice, with the potential for bilirubin encephalopathy, is a possible complication of G-6-PD deficiency that has been noted for many affected population groups, as reviewed previously.26,27 In Nigeria, where the G-6-PD A– variant is encountered, a high incidence of associated hemolysis and kernicterus has been noted.28 It is not surprising that G-6-PD A– is now encountered in geographic regions inhabited by descendents of original Africans. It has been estimated that 30 000 to 40 000 G-6-PD-deficient African American male infants are born each year in the United States.29 In a recent report on the United States-based Pilot Kernicterus Registry,2 G-6-PD deficiency was shown to affect 31.5% of 61 patients with kernicterus (of a total of 90) who were readmitted in the first 7 days of life. Although the incidence of G-6-PD deficiency in the full complement of 90 neonates in that study is not known and may be lower than 31.5% (although not lower than 21%), we do not know by which methods G-6-PD was tested, and the population included in the registry was gathered in a nonsystematic manner, there does seem to be a connection between G-6-PD deficiency and the development of kernicterus within the registry. G-6-PD deficiency has been emphasized as a major cause of severe hyperbilirubinemia in general12,30 and among African American neonates in particular.29,31 The Centers for Disease Control and Prevention recently included the enzyme deficiency in a mnemonic regarding the causes of hyperbilirubinemia, designed to increase physician awareness of the condition.32 It is remarkable that, despite apparent awareness on the part of some authorities, to date there have been no prospectively designed, cohort studies definitively evaluating the risk of hyperbilirubinemia in this population subgroup.

Some reasons for the lack of concern regarding G-6-PD deficiency among African American neonates may include early reports that hyperbilirubinemia rates were not significantly higher among G-6-PD-deficient neonates, compared with those with normal enzyme activity.11,33,34 More recent statements suggested that, with A– G-6-PD deficiency, spontaneous hemolysis may occur among premature but not term infants.35 Furthermore, as a group, black neonates in the United States (the majority of whom are not G-6-PD-deficient) have a lower incidence of hyperbilirubinemia than do their neonates.
white or Asian counterparts. In addition, only some G-6-PD-deficient neonates develop hyperbilirubinemia. However, other reports and the data reported here provide sufficient evidence to offset these limitations. Our data establish an increased frequency of hyperbilirubinemia requiring phototherapy among G-6-PD-deficient infants, but not increased bilirubin levels, compared with control subjects. Our study clearly documents a prevalence of G-6-PD deficiency among neonates for whom hyperbilirubinemia was documented that was higher than that for the entire cohort. The rate of hemolysis was higher in the G-6-PD-deficient group than in the control group. In this survey, no cases of severe hemolysis (akin to favism) or kernicterus were encountered. The latter observation is not surprising, because kernicterus is an extremely rare, although highly important, condition and the chance of a case occurring among 64 neonates is very small. Furthermore, vigilant neonatal nursery care was combined with cautious postdischarge follow-up monitoring, the specific aim of which was to prevent severe hyperbilirubinemia.

One possible reason for the apparent contrast between the current data and those of the earlier studies may be that, in the older studies, bilirubin values were analyzed by using mean values during a particular 24-hour period. In contrast, we plotted bilirubin values on the hour-of-life nomogram and defined hyperbilirubinemia according to the highest noted bilirubin percentile for the hour of life, which is a much more sensitive approach. Another advantage of our method was that we were able to identify hyperbilirubinemia among neonates who developed early jaundice and for whom phototherapy was instituted before the routine predischarge bilirubin screening.

In this study, we used ETCOc measurements as our primary means of evaluating hemolysis. The median ETCOc value for the G-6-PD-deficient neonates was ~14% higher than that for the control population. However, because the pathogenesis of hyperbilirubinemia is multifactorial, increased heme catabolism or bilirubin production does not necessarily indicate that the plasma bilirubin concentrations, or total bilirubin load, should be 14% higher. Heme catabolism is only 1 factor contributing to plasma bilirubin concentrations and does not reflect subsequent steps in the elimination of bilirubin, such as its uptake into hepatocytes or its conjugation, deficiencies of which may also contribute to the plasma total unconjugated bilirubin concentrations. Indeed, a tendency for decreased bilirubin conjugation among G-6-PD-deficient neonates was reported, the result of an interaction between G-6-PD deficiency and TA promoter polymorphism of the gene encoding the bilirubin-conjugating enzyme uridine diphosphate-glucuronosyltransferase 1A1. Because the PTB level at any time point represents a balance between the production and elimination of bilirubin, an apparent modest increase in hemolysis may have a major effect on PTB concentrations under conditions of diminished bilirubin conjugation. Conversely, severely increased hemolysis may have minimal effects on PTB levels under conditions of excellent bilirubin conjugation and excretion. Superimposition of additional interrogenic factors increasing the bilirubin load, such as hemolysis attributable to recognized or unidentifiable chemical triggers or infection or decreased bilirubin conjugation secondary to prematurity or uridine diphosphate-glucuronosyltransferase 1A1 promoter polymorphism, as seen in Gilbert's syndrome, may further upset the equilibrium between the production and elimination of bilirubin, with the potential for extreme hyperbilirubinemia and kernicterus. For these reasons, the moderately increased ETCOc values are of concern, especially because increased hemolysis has been recognized as a risk factor for kernicterus. As stated above, neonates born to smoking mothers were not included in the ETCOc analyses. However, the number of smoking mothers in the G-6-PD-deficient group was approximately one-half of that in the control group (not statistically significant) and only 5 G-6-PD-deficient infants were excluded from these analyses, which likely had a minimal effect on the results.

In this study, we did not routinely assess hemato logic parameters associated with hemolysis among older pediatric patients or adults. Among newborns, there may be overlap between the profiles associated with hemolytic and nonhemolytic states. The reticulocyte count is frequently used as a reflection of hemolysis, because it is regarded as a measure of the bone marrow's compensation for anemia. However, this count may be inaccurate among newborns, because it depends on the bone marrow's capacity to respond, the lag time between the hemolytic event and the response, and the effect of nonhemolytic causes of anemia stimulating a reticulocytic reaction. Although no attempt was made to fractionate the PTB levels into direct and indirect components, it was presumed that PTB levels represent primarily unconjugated bilirubin.

It is intriguing that, despite the increased hemolysis and higher incidence of hyperbilirubinemia in the G-6-PD-deficient group, the severity of hyperbilirubinemia, once it developed, was similar in the study and control groups. Not only did all neonates who met the criteria for phototherapy respond to this treatment, but the age at onset, duration of treatment, age at the termination of treatment, and hourly rate of bilirubin decrease were comparable. Similarly, PTB levels at the onset of treatment and the maximal noted PTB levels were in the same ranges for the 2 groups. Although it is possible that there was more efficient hepatic handling of bilirubin among the G-6-PD-deficient neonates who were receiving phototherapy, compared with control subjects, this study was not designed to evaluate bilirubin conjugation or excretion. In previous studies that demonstrated a tendency for diminished bilirubin conjugation in the mechanism of jaundice among G-6-PD-deficient neonates, sampling was performed before the institution of phototherapy; therefore, results should not be extrapolated to neonates.
in the current study, who were receiving photother-
apy.

Because only some G-6-PD-deficient neonates de-
velop hyperbilirubinemia, additional ieterogenic fac-
tors have been sought. It has been questioned
whether, within the G-6-PD-deficient subset, those
with very low enzyme activity levels may have a
higher incidence of, or more severe, jaundice, com-
pared with those at the upper end of the spectrum.
Studies to date have been inconclusive, and the level
of enzyme activity in G-6-PD-deficient erythrocytes
does not bear a consistent relationship to either the
degree of hemolysis or the development of hyperbi-
lorubinemia.\textsuperscript{33,47–49} Correlation analyses in the cur-
rent study demonstrated no effect of residual G-6-PD
activity on the severity of bilirubinemia grading.
Similarly, the lack of correlation of ETCO\textsubscript{c} values
and bilirubin grading confirms observations show-
ing that the increased hemolysis found in association
with G-6-PD deficiency may not be the primary fac-
tor involved in the pathogenesis of jaundice, in con-
trast to G-6-PD-normal populations, in which in-
creased hemolysis plays a direct role in the mecha-
nism of neonatal jaundice.\textsuperscript{47}

In most G-6-PD A– cases, a 202A mutation is
encountered; 968C and 680T mutations have also
been found, however.\textsuperscript{16,50} We did not attempt to
perform genotypic analysis in this study, and it is
possible that 1 of these G-6-PD A– genotypes was
over-represented in the hyperbilirubinemic group.
The aim of the study was to determine, in a practical
clinical setting, whether African American neonates
with G-6-PD deficiency were at increased risk for
hyperbilirubinemia. Although practicing pediatri-
cians could safely presume that almost all G-6-PD-
deficient African American neonates they would en-
counter would have the A– variety, information
regarding genotypes would not be available on a
daily basis. In future studies, consideration should be
given to addressing the issue of the various geno-
types and their possible effects on the development
of hyperbilirubinemia.

**CONCLUSIONS**

Our data have highlighted a subgroup of neonates
within the African American community who may
be at risk for hyperbilirubinemia and its complica-
tions. Fortunately, kernicterus seems to be a rare
condition; to eliminate it completely, however, there
is a need to monitor these neonates vigilantly, to
detect hyperbilirubinemia and treat it without delay.
The World Health Organization has recommended
screening for G-6-PD deficiency in geographic areas
where the incidence of the condition among male
subjects exceeds 3 to 5\%.\textsuperscript{51} Although the issue was
not addressed in the current study, future studies
and health planning programs should consider as-
sessment of the cost-benefit ratio for screening in this
group. The degree to which female neonates in this
population are affected remains to be ascertained.
A high degree of awareness is necessary to minimize
the consequences of G-6-PD deficiency.

**ACKNOWLEDGMENT**

The study was supported in part by a grant from Natus Med-
ical Inc (San Carlos, CA).

**REFERENCES**

1. Johnson LH, Brown AK. A pilot registry for acute and chronic ker-
nicterus in term and near term infants. Pediatrics. 1999;104(suppl):736A
2. Johnson LH, Bhutani VK, Brown AK. System-based approach to man-
2002;140:396–403
3. Penn AA, Enzmann DR Hahn JS, Stevenson DK. Kernicterus in a full
jaundice due to G6PD deficiency causing kernicterus in a female new-
5. Carpentieri U, Moore RL, Nichols MM. Kernicterus in a newborn fe-
6. Moore AM, Perlman M. Symptomatic hypoglycemia in otherwise
7. MacDonald MG. Hidden risks: early discharge and bilirubin toxicity
due to glucose-6-phosphate dehydrogenase deficiency. Pediatrics. 1995;
96:734–738
8. Aflifors CE, Herbsman O. Unbound bilirubin in a term newborn with
Arch Int Med. 1962;109:220–234
10. Heller P, Best WR, Nelson RB, Becktel J. Clinical implications of sickle-
cell trait and glucose-6-phosphate dehydrogenase deficiency in hospi-
11. O’Flynn MED, Hsia DY-H. Serum bilirubin levels and glucose-6-
phosphate dehydrogenase deficiency in newborn American Negroes.
Neonatology: Pathophysiology and Management of the Newborn. Phila-
delphia, PA: Lippincott Williams & Wilkins; 1999:765–819
17. Bhutani VK, Johnson L, Sivieri EM. Predictive ability of a predischarge
parameter: management of hyperbilirubinemia in the healthy term
18. American Academy of Pediatrics, Provisional Committee for Quality
Improvement and Subcommittee on Hyperbilirubinemia. Practice param-
eter: management of hyperbilirubinemia in the healthy term newborn.
New York, NY: Grune & Stratton; 1984:68–71
glucose-6-phosphate dehydrogenase-normal and -deficient neonates
21. Vreman HJ, Mahoney JJ, Stevenson DK. Carbon monoxide and carboxy-
22. Stevenson DK, Vreman HJ. Carboxyhemoglobin and bilirubin produc-
1994;40:1934–1939
1994;40:1927–1933
25. Alden ER, Lynch SR, Wennberg RP. Carboxyhemoglobin determination
26. Valaes T. Severe neonatal jaundice associated with glucose-6-phosphate
dehydrogenase deficiency: pathogenesis and global epidemiology. Acta
Paediatr Suppl. 1994;394:58–76
27. Kaplan M, Hammerman C. Severe neonatal hyperbilirubinemia: a po-
tential complication of glucose-6-phosphate dehydrogenase deficiency.
28. Slusher TM, Vreman HJ, McLaren DW, Levison LJ, Brown AK, Stevens-
on DK. Glucose-6-phosphate dehydrogenase deficiency and carboxy-


Hyperbilirubinemia Among African American, Glucose-6-Phosphate Dehydrogenase-Deficient Neonates

Michael Kaplan, Marguerite Herschel, Cathy Hammerman, James D. Hoyer and David K. Stevenson

*Pediatrics* 2004;114:e213

DOI: 10.1542/peds.114.2.e213

Updated Information & Services

including high resolution figures, can be found at:
/content/114/2/e213.full.html

References

This article cites 44 articles, 17 of which can be accessed free at:
/content/114/2/e213.full.html#ref-list-1

Citations

This article has been cited by 4 HighWire-hosted articles:
/content/114/2/e213.full.html#related-urls

Subspecialty Collections

This article, along with others on similar topics, appears in the following collection(s):

- Fetus/Newborn Infant
  /cgi/collection/fetus:newborn_infant_sub
- Hyperbilirubinemia
  /cgi/collection/hyperbilirubinemia_sub

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
/site/misc/Permissions.xhtml

Reprints

Information about ordering reprints can be found online:
/site/misc/reprints.xhtml

PEDIATRICS is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. PEDIATRICS is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2004 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 0031-4005. Online ISSN: 1098-4275.
Hyperbilirubinemia Among African American, Glucose-6-Phosphate Dehydrogenase-Deficient Neonates

Michael Kaplan, Marguerite Herschel, Cathy Hammerman, James D. Hoyer and David K. Stevenson

*Pediatrics* 2004;114:e213
DOI: 10.1542/peds.114.2.e213

The online version of this article, along with updated information and services, is located on the World Wide Web at:
/content/114/2/e213.full.html